دورية أكاديمية
Ginseng-containing traditional medicine preparations in combination with fluoropyrimidine-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis.
العنوان: | Ginseng-containing traditional medicine preparations in combination with fluoropyrimidine-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis. |
---|---|
المؤلفون: | Jiaqi Hu, Mengqi Cheng, Yue Li, Bolun Shi, Shulin He, Ziang Yao, Juling Jiang, Huibo Yu, Zhongning He, Yuwei Zhao, Honggang Zheng, Baojin Hua, Rui Liu |
المصدر: | PLoS ONE, Vol 18, Iss 4, p e0284398 (2023) |
بيانات النشر: | Public Library of Science (PLoS), 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Medicine LCC:Science |
مصطلحات موضوعية: | Medicine, Science |
الوصف: | BackgroundGinseng-containing traditional medicine preparations (G-TMPs) in combination with fluoropyrimidine-based chemotherapy (FBC) are well-known treatments for advanced gastric cancer (AGC), with a superior efficacy to FBC alone. However, evidence regarding their efficacy remains limited. The purpose of this meta-analysis is to evaluate the efficacy and safety of G-TMPs in combination with FBC for the treatment of AGC.MethodsEight electronic databases were searched for randomized controlled trials (RCTs) using G-TMPs with FBC for the treatment of AGC. The primary outcome included the tumor response, while the secondary outcomes included the quality of life (QoL), proportions of peripheral blood lymphocytes, adverse drug reactions (ADRs), and levels of cancer biomarkers. The quality of evidence for each outcome was assessed using GRADE profilers.ResultsA total of 1,960 participants were involved in the 26 RCTs included. Patients treated with FBC plus G-TMPs had better objective response (risk ratio [RR] = 1.23, 95% confidence interval [CI]: 1.13 to 1.35, p < 0.00001) and disease control (RR = 1.13, 95% CI: 1.08 to 1.19, p < 0.00001) rates than those treated with FBC alone. Additionally, the combination group had a better QoL, higher proportions of CD3+ T cells, CD4+ T cells, and natural killer cells, as well as a higher CD4+/CD8+ T-cell ratio. Furthermore, lower levels of CA19-9, CA72-4, and CEA were confirmed in the combination treatment group. In addition, G-TMPs reduced the incidence of ADRs during chemotherapy.ConclusionIn combination with FBC, G-TMPs can potentially enhance efficacy, reduce ADRs, and improve prognosis for patients with AGC. However, high-quality randomized studies remain warranted.Systematic review registrationPROSPERO Number: CRD42021264938. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1932-6203 |
Relation: | https://doaj.org/toc/1932-6203 |
DOI: | 10.1371/journal.pone.0284398 |
URL الوصول: | https://doaj.org/article/c3740b65eb534eda9c69b4587b1b5cef |
رقم الأكسشن: | edsdoj.3740b65eb534eda9c69b4587b1b5cef |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 19326203 |
---|---|
DOI: | 10.1371/journal.pone.0284398 |